Apparently, nothing interesting is happening at Kroger (KR). The stock has been strictly trading sideways since early 2017, except for some sudden declines post some earnings results. During the last reported quarter, the retail store chain missed its mark on revenue and identical-store sales and investors had sent the stock tumbling 9%.
It’s high time Kroger give investors some fodder to inspire a stock rally.
Following disappointing second-quarter results, Kroger CEO Rodney McMullen had stated that the company is already working on restructuring, which should be visible in numbers from the third quarter. If Rodney delivers on this promise, that should act as enough fodder.
Kroger hasn’t been as profitable as its rivals over the recent quarters. In the second quarter, the company reported comp sales growth of just 1.6%, whereas rival Walmart (WMT) posted a growth of 4.5% in the US. From the numbers, it may be suspected that Walmart is actually eating into Kroger’s grocery business.
Rising retail competition continue to act as a headwind for Kroger, though it has been trying its bit to stay relevant. In order to ramp up doorstep deliveries, Kroger this year made a deal with autonomous vehicle startup Nuro. Apart from this, the company has partnered with Ocado, a UK-basked online rival to boost its digital operations.
Separately, Kroger acquired Home Chef in May. The acquisition of the meal-kit provider was aimed at improving its omnichannel presence. However, benefits from these acquisitions are yet to make their way into Kroger’s balance sheet.
As Kroger reports third-quarter results on Thursday before the market opens, analysts expect the company to post earnings of 43 cents per share on a revenue of $27.58 billion.
The stock has 5 BUY ratings; 5 HOLD ratings and 1 SELL rating. It has an average 12-month price target of $30.7, which is at a 4% upside from the current trading price.
Get access to timely and accurate verbatim transcripts that are published within hours of the event
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
